The US FDA's popular 505(b)(2) new drug application pathway, a streamlined process most often used for new forms and formulations of existing drugs, does not produce shorter review times, an analysis by the Tufts Center for Drug Development and Sakai Regulatory Consulting found.
While the pathway allows for less extensive submissions than is required for new molecular entities (NMEs), "drug developers should not...








